These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38644793)

  • 1. 'Substantial clinical benefit' and 'substantial clinical worsening' cutoff of Vitiligo Impact Scale (VIS)-22 change scores.
    Gupta V; Taneja N; Sati HC; Sreenivas V; Ramam M
    Br J Dermatol; 2024 Jul; 191(2):307-308. PubMed ID: 38644793
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument.
    Gupta V; Sreenivas V; Mehta M; Khaitan BK; Ramam M
    Br J Dermatol; 2014 Nov; 171(5):1084-90. PubMed ID: 24805089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage.
    Ongenae K; Dierckxsens L; Brochez L; van Geel N; Naeyaert JM
    Dermatology; 2005; 210(4):279-85. PubMed ID: 15942213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do Vitiligo Impact Scale-22 scores mean? Studying the clinical interpretation of scores using an anchor-based approach.
    Gupta V; Sreenivas V; Mehta M; Ramam M
    Br J Dermatol; 2019 Mar; 180(3):580-585. PubMed ID: 30085349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Vitiligo Day-A grassroots campaign to improve the quality of life of vitiligo patients.
    Valle Y
    Dermatol Ther; 2019 Sep; 32(5):e13050. PubMed ID: 31369192
    [No Abstract]   [Full Text] [Related]  

  • 6. To what extent is quality of life impaired in vitiligo? A multicenter study on Italian patients using the dermatology life quality index.
    Ingordo V; Cazzaniga S; Medri M; Raone B; Digiuseppe MD; Musumeci ML; Romano I; Fai D; Pellegrino M; Pezzarossa E; Di Lernia V; Peccerillo F; Battarra VC; Sirna R; Patrizi A; Naldi L
    Dermatology; 2014; 229(3):240-7. PubMed ID: 25358871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire.
    Augustin M; Gajur AI; Reich C; Rustenbach SJ; Schaefer I
    Dermatology; 2008; 217(2):101-6. PubMed ID: 18451647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool.
    Salzes C; Abadie S; Seneschal J; Whitton M; Meurant JM; Jouary T; Ballanger F; Boralevi F; Taieb A; Taieb C; Ezzedine K
    J Invest Dermatol; 2016 Jan; 136(1):52-8. PubMed ID: 26763423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness-to-pay and quality of life in patients with vitiligo.
    Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
    Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial burden of lichen planus pigmentosus is similar to vitiligo, but greater than melasma: A cross-sectional study from a tertiary-care center in north India.
    Gupta V; Yadav D; Satapathy S; Upadhyay A; Mahajan S; Ramam M; Sharma VK
    Indian J Dermatol Venereol Leprol; 2021; 87(3):341-347. PubMed ID: 33943064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermoscopy as an evolving tool to assess vitiligo activity.
    Jha AK; Sonthalia S; Lallas A
    J Am Acad Dermatol; 2018 May; 78(5):1017-1019. PubMed ID: 29229577
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo.
    Krishna GS; Ramam M; Mehta M; Sreenivas V; Sharma VK; Khandpur S
    Indian J Dermatol Venereol Leprol; 2013; 79(2):205-10. PubMed ID: 23442459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychiatric morbidity and quality of life in Vitiligo: a case controlled study].
    Mechri A; Amri M; Douarika AA; Ali Hichem BH; Zouari B; Zili J
    Tunis Med; 2006 Oct; 84(10):632-5. PubMed ID: 17193855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo.
    Rzepecki AK; McLellan BN; Elbuluk N
    J Drugs Dermatol; 2018 Jun; 17(6):688-691. PubMed ID: 29879259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and treatment outcomes of vitiligo from the patients' perspective: results of a national survey in Germany.
    Radtke MA; Schäfer I; Gajur AI; Augustin M
    Dermatology; 2010; 220(3):194-200. PubMed ID: 20203472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stigmatisation, Avoidance Behaviour and Difficulties in Coping are Common Among Adult Patients with Vitiligo.
    Krüger C; Schallreuter KU
    Acta Derm Venereol; 2015 May; 95(5):553-8. PubMed ID: 25269389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Perspectives: What is Vitiligo?
    Pediatr Dermatol; 2015; 32(6):e328-9. PubMed ID: 26584709
    [No Abstract]   [Full Text] [Related]  

  • 18. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran.
    Dolatshahi M; Ghazi P; Feizy V; Hemami MR
    Indian J Dermatol Venereol Leprol; 2008; 74(6):700. PubMed ID: 19177700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life for Korean patients with vitiligo: Skindex-29 and its correlation with clinical profiles.
    Kim DY; Lee JW; Whang SH; Park YK; Hann SK; Shin YJ
    J Dermatol; 2009 Jun; 36(6):317-22. PubMed ID: 19500179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hidden victims of childhood vitiligo: impact on parents' mental health and quality of life.
    Amer AA; Mchepange UO; Gao XH; Hong Y; Qi R; Wu Y; Cai Y; Zhai J; Chen HD
    Acta Derm Venereol; 2015 Mar; 95(3):322-5. PubMed ID: 25110968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.